Nuvectis Pharma Investor Presentation Deck
Nuvectis Investment Highlights
Precision medicine pipeline for serious conditions of unmet medical need in oncology
2023 Milestones
NXP800
NXP900
Management Team with
Strong Track Record
NuvectisPharma, Inc.
Initiated NXP800 Phase 1b in ARID1a-mutated ovarian cancers, additional tumor types to follow
FDA clearance for NXP900 IND achieved, commencement of the Phase 1a study 3Q2023
Clinical and preclinical data presentations at medical conferences
* Fast Track Designation for platinum-resistant, ARID1A-mutated ovarian carcinoma
Phase 1b study conducted in collaboration with ENGOT/GOG-F consortia
ā Orphan Drug Designation for the treatment of cholangiocarcinoma
Highly selective compound, differentiated from other YES1/SRC-kinase inhibitors
Phase 1a initiated
3 approved drugs in 4 indications in the US and EU
* Generated significant shareholder value
Stock added to the Russell 2000 Index in June 2023
24View entire presentation